Detalhe da pesquisa
1.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605176
2.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Blood
; 130(17): 1889-1897, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29074595
3.
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Hematol Oncol
; 37(4): 352-359, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385336
4.
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
Blood
; 134(23): 2107-2111, 2019 12 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578205
5.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
J Clin Oncol
; 39(36): 4049-4060, 2021 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34709929
6.
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial.
Eur Urol
; 75(1): 63-71, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30274699